Published in J Appl Physiol (1985) on March 12, 2015
Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial. J Pain Symptom Manage (2016) 0.76
Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial. J Pain Symptom Manage (2017) 0.75
Standardisation of spirometry. Eur Respir J (2005) 48.20
Psychophysical bases of perceived exertion. Med Sci Sports Exerc (1982) 30.13
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med (2003) 8.83
The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain (1983) 7.46
A systematic review of the use of opioids in the management of dyspnoea. Thorax (2002) 4.10
An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med (2008) 3.98
An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med (2012) 3.62
The number of alveoli in the human lung. Am J Respir Crit Care Med (2003) 2.93
Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ (2003) 2.40
Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD (2005) 2.14
Can age and sex explain the variation in COPD rates across large urban cities? A population study in Canada. Int J Tuberc Lung Dis (2011) 2.01
Using laboratory models to test treatment: morphine reduces dyspnea and hypercapnic ventilatory response. Am J Respir Crit Care Med (2011) 1.66
Inhaled fentanyl as a method of analgesia. Anaesthesia (1990) 1.60
Restricted spirometry in the Burden of Lung Disease Study. Int J Tuberc Lung Dis (2012) 1.55
American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest (2010) 1.46
Perineurial defect and peripheral opioid analgesia in inflammation. J Neurosci (1995) 1.45
Fentanyl for the relief of refractory breathlessness: a systematic review. J Pain Symptom Manage (2013) 1.44
Physiological mechanisms of sex differences in exertional dyspnoea: role of neural respiratory motor drive. Exp Physiol (2013) 1.44
The microanatomy of the alveolar duct system. Thorax (1970) 1.44
Pathophysiology of activity limitation in patients with interstitial lung disease. Chest (1996) 1.41
Neurogenic inflammation in the airways. Respir Physiol (2001) 1.26
Effect of inhaled and systemic opiates on responses to inhaled capsaicin in humans. J Appl Physiol (1985) (1988) 1.25
Reliability and validity of the perioperative opioid-related symptom distress scale. Anesth Analg (2004) 1.16
Pulmonary mechanics during exercise in normal males. J Appl Physiol Respir Environ Exerc Physiol (1980) 1.12
Rapid upregulation of mu opioid receptor mRNA in dorsal root ganglia in response to peripheral inflammation depends on neuronal conduction. Neuroscience (2004) 1.10
Airway opioid receptors mediate inhibition of cough and reflex bronchoconstriction in guinea pigs. J Pharmacol Exp Ther (1990) 1.09
Mechanisms of activity-related dyspnea in pulmonary diseases. Respir Physiol Neurobiol (2009) 1.08
Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax (1995) 1.06
Opioids and sensory nerves. Handb Exp Pharmacol (2009) 1.06
Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest (1993) 1.04
The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. A comparison of three different exercise tests. Am J Respir Crit Care Med (2000) 1.03
Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax (1996) 1.01
Opioid inhibition of neurally mediated mucus secretion in human bronchi. Lancet (1989) 1.01
Qualitative aspects of exertional dyspnea in patients with interstitial lung disease. J Appl Physiol (1985) (1998) 1.01
Aerosol deposition considerations in inhalation therapy. Chest (1985) 1.01
Mechanisms of dyspnea. Chest (2010) 1.00
Neurogenic plasma extravasation: inhibition by morphine in guinea pig airways in vivo. J Appl Physiol (1985) (1989) 1.00
Using opioids to treat dyspnea in advanced COPD: attitudes and experiences of family physicians and respiratory therapists. Can Fam Physician (2012) 0.99
Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. Eur Respir J (1997) 0.99
Respiratory sensation during chest wall restriction and dead space loading in exercising men. J Appl Physiol (1985) (2000) 0.98
Low-dose nebulized morphine does not improve exercise in interstitial lung disease. Am J Respir Crit Care Med (1995) 0.98
Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. Respir Med (2010) 0.93
Quality of life and health status in interstitial lung diseases. Curr Opin Pulm Med (2006) 0.92
Peripheral versus central cardiorespiratory effects of morphine. Neuropharmacology (1982) 0.92
Dyspnea in interstitial lung disease. Curr Opin Support Palliat Care (2008) 0.91
Spirometrically-defined restrictive ventilatory defect: population variability and individual determinants. Prim Care Respir J (2012) 0.91
External thoracic restriction, respiratory sensation, and ventilation during exercise in men. J Appl Physiol (1985) (1999) 0.90
Exercise limitation in interstitial lung disease - mechanisms, significance and therapeutic options. Chron Respir Dis (2010) 0.90
Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest (2010) 0.87
Physical training for interstitial lung disease. Cochrane Database Syst Rev (2008) 0.87
Opioid therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary disease: patients' experiences and outcomes. CMAJ Open (2013) 0.85
Inhibition of cholinergic neurotransmission in human airways by opioids. J Appl Physiol (1985) (1992) 0.85
Lung volumes and expiratory flow limitation during exercise in interstitial lung disease. J Appl Physiol (1985) (1994) 0.84
Clinical exercise testing in interstitial lung disease. Clin Chest Med (1994) 0.83
Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci (2000) 0.82
Management of dyspnea in interstitial lung disease. Curr Opin Support Palliat Care (2010) 0.82
Effects of inhaled nebulized morphine on ventilation and breathlessness during exercise in healthy man. Clin Sci (Lond) (1995) 0.82
Exercise and interstitial lung disease. Curr Opin Pulm Med (1998) 0.81
Cigarette smoke-induced airway goblet cell secretion: dose-dependent differential nerve activation. Am J Physiol (1992) 0.81
Effects of pregnancy, obesity and aging on the intensity of perceived breathlessness during exercise in healthy humans. Respir Physiol Neurobiol (2009) 0.81
Peripheral sensitization increases opioid receptor expression and activation by crotalphine in rats. PLoS One (2014) 0.80
Doctors' attitudes towards prescribing opioids for refractory dyspnoea: a single-centred study. BMJ Support Palliat Care (2014) 0.80
Respiratory drive and ventilatory pattern during exercise in interstitial lung disease. Bull Eur Physiopathol Respir (1981) 0.79
Cough sensors. III. Opioid and cannabinoid receptors on vagal sensory nerves. Handb Exp Pharmacol (2009) 0.79
Effects of κ- and μ-opioid agonists on cholinergic neurotransmission and contraction in isolated bovine trachealis. Respir Physiol Neurobiol (2012) 0.78
The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir Care (2007) 0.78
Characterization of non-conventional opioid binding sites in rat and human lung. Eur J Pharmacol (1994) 0.78
Local pulmonary opioid network in patients with lung cancer: a putative modulator of respiratory function. Pharmacol Rep (2010) 0.78
Modulation of acetylcholine release from parasympathetic nerves innervating guinea-pig and human trachea by endomorphin-1 and -2. Eur J Pharmacol (1999) 0.78
Pulmonary opiate receptor activation evokes a cardiorespiratory reflex. Eur J Pharmacol (1982) 0.77
Binding of [3H][D-Ala2, MePhe4, Gly-ol5] enkephalin, [3H][D-Pen2, D-Pen5]enkephalin, and [3H]U-69,593 to airway and pulmonary tissues of normal and sensitized rats. Peptides (1997) 0.77
Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany. J Palliat Med (2012) 0.77
Capsaicin-induced bronchoconstriction in the guinea-pig: contribution of vagal cholinergic reflexes, local axon reflexes and their modulation by BW443C81. Br J Pharmacol (1992) 0.76
Opioid receptor bronchial tree: current science. Curr Opin Support Palliat Care (2014) 0.76
Nebulized medications for the treatment of dyspnea: a literature review. J Aerosol Med Pulm Drug Deliv (2014) 0.76
Physiological mechanisms of dyspnea during exercise with external thoracic restriction: role of increased neural respiratory drive. J Appl Physiol (1985) (2013) 0.76
Quantitative autoradiography of peripheral opioid binding sites in rat lung. Eur J Pharmacol (1996) 0.76
Effect of BW443C81, a novel opioid, on non-cholinergic bronchoconstrictor responses and neurogenic plasma extravasation in the guinea pig. Agents Actions (1992) 0.76